Etrolizumab, CAS 1044758-60-2

Product Description: Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD)[1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Tang MT, et, al. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease. Aliment Pharmacol Ther. 2018 Jun;47(11):1440-1452./[2]Stefanich EG, et, al. A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol. 2011 Apr;162(8):1855-70.

CAS Number: 1044758-60-2

Molecular Weight: N/A

Compound Purity: 99.56

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Integrin

• Artikelnummer: MEXHY-P9984-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9984-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated